Dmitriy Zamarin

Dmitriy Zamarin, MD PhD

Hematology-Oncology, Icahn School of Medicine at Mount Sinai

Planning Committee

Biography

Dmitriy Zamarin MD PhD is Professor of Oncology, Section Head of Gynecologic Medical Oncology, and co-director of Center of Excellence for Gynecologic Cancers at the Tisch Cancer Center at Icahn School of Medicine at Mount Sinai. Dr. Zamarin obtained his MD and PhD degrees from the Mount Sinai School of Medicine. He completed residency in Internal Medicine at the Mount Sinai Hospital and fellowship in Hematology/Oncology at the Memorial Sloan Kettering Cancer Center. He spent a decade as a faculty and Translational Research Director in Gynecologic Medical Oncology at the Memorial Sloan Kettering Cancer Center before transitioning to his current role in September of 2023. Dr. Zamarin has served as a principal investigator and a translational chair on multiple institutional and cooperative group clinical trials and serves as the translational research co-chair on the NRG Oncology Cervical Cancer committee. His clinical and laboratory research is focused on cancer cell-intrinsic mechanisms of immune recognition and resistance and development of novel therapeutics. Dr. Zamarin has received awards and funding from multiple organizations including Damon Runyon Foundation, Ovarian Cancer Research Alliance, Department of Defense, and the National Cancer Institute and is a member of the American Society for Clinical Investigation.

Financial Disclosure

Xencor, Memgen, BioInvent, Daiichi Sankyo, Gilead, Replimune, GSK, Eli Lilly

Consultant

Tikva Allocell, Calidi, OverT, Everest

Advisor

Volastra

Grant Or Contract

Tubulis

Grant Or Contract

Xencor

Grant Or Contract

OverT

Ownership Interest

Gilead

Consultant

GSK

Consultant

Calidi

Ownership Interest

Zymeworks

Grant Or Contract

Daiichi

Consultant

NextCure

Grant Or Contract

Eli Lilly

Consultant

Everest

Consultant